학술논문
963MO Naxitamab for the treatment of refractory/relapsed high-risk neuroblastoma (HR NB): Updated efficacy and safety data from the international, multicenter phase II trial 201
Document Type
Abstract
Author
Source
In Annals of Oncology September 2021 32 Supplement 5:S833-S833
Subject
Language
ISSN
0923-7534